Select status:
Sort by:
Filter by last updated date

Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and May 2019

Filter by type
Showing 1 to 10 of 431
Title Reference number Published Last updated
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) Reference number:TA582 TA00582 Published:May 2019 20190501 Last updated:May 2019 20190524
Enzalutamide for hormone-relapsed non-metastatic prostate cancer Reference number:TA580 TA00580 Published:May 2019 20190501 Last updated:May 2019 20190515
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma Reference number:TA581 TA00581 Published:May 2019 20190501 Last updated:May 2019 20190515
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Reference number:TA579 TA00579 Published:May 2019 20190501 Last updated:May 2019 20190508
Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation Reference number:TA578 TA00578 Published:May 2019 20190501 Last updated:May 2019 20190501
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma Reference number:TA577 TA00577 Published:April 2019 20190401 Last updated:April 2019 20190424
Certolizumab pegol for treating moderate to severe plaque psoriasis Reference number:TA574 TA00574 Published:April 2019 20190401 Last updated:April 2019 20190417
Tildrakizumab for treating moderate to severe plaque psoriasis Reference number:TA575 TA00575 Published:April 2019 20190401 Last updated:April 2019 20190417
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) Reference number:TA576 TA00576 Published:April 2019 20190401 Last updated:April 2019 20190417
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma Reference number:TA573 TA00573 Published:April 2019 20190401 Last updated:April 2019 20190410